FiE 2025: Cabio Biotech’s HMOs fuel new preventive nutrition opportunities
15 Jan 2026 | Cabio Biotech
On the showroom floor, we caught up with Wen Xiong, product engineer at Cabio Biotech, to discuss the company’s human milk oligosaccharide (HMO) portfolio. Xiong detailed how Cabio Biotech selects and produces key HMO structures, including its 2’-fucosyllactose, lacto-N-tetraose, and 3’-sialyllactose, to ensure safety, stability, and efficacy. Wenzhong also discussed growing interest in preventive nutrition, positioning HMOs as natural, human-origin solutions that can expand beyond infant formula into supplements and broader nutrition categories.
Subscribe to our newsletters
By continuing to browse our site you agree to our Privacy Statement













